Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination With NewAmsterdam Pharma Holding B.V.

Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC) (“FLAC”), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, announced today that its shareholders voted to approve the proposed business combination (the “Business Combination”) with NewAmsterdam Pharma Holding B.V. (“NewAmsterdam”), a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases.

More than 90% of the votes cast at the Extraordinary General Meeting of Shareholders (the “General Meeting”) were cast in favor of the previously announced business combination. FLAC shareholders also voted to approve all other proposals presented at the General Meeting. The formal results of the vote will be included in a Current Report on Form 8-K to be filed by FLAC with the Securities and Exchange Commission (the “SEC”).

In connection with the Business Combination, the holders of approximately 32% of FLAC Class A ordinary shares exercised their right to redeem their shares for cash.

The business combination is expected to close on November 22, 2022, subject to the satisfaction or waiver of customary closing conditions.

Upon closing, the ordinary shares and redeemable warrants of the combined company, NewAmsterdam Pharma Company N.V. (the “Company”), will be listed on The Nasdaq Stock Market LLC under the ticker symbols “NAMS” and “NAMSW” respectively, and are anticipated to begin trading on November 23, 2022. Any FLAC units will automatically separate into the equivalent Class A ordinary shares and warrants upon the consummation of the business combination. 

“We continue to be grateful to our shareholders for their continued support,” said James Topper, M.D., Ph.D., Managing Partner at Frazier Healthcare Partners and Chairman of the Board of Directors and Chief Executive Officer of FLAC.